These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7593495)

  • 21. Effects of pentoxifylline in the prevention of ovarian hyperstimulation syndrome in a rabbit model.
    Serin IS; Ozçelik B; Bekyurek T; Ozturk F; Koc N; Sahin Y
    Gynecol Endocrinol; 2002 Oct; 16(5):355-9. PubMed ID: 12587528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC).
    Morris RS; Wong IL; Do YS; Hsueh WA; Lobo RA; Sauer MV; Pauslon RJ
    Adv Exp Med Biol; 1995; 377():391-8. PubMed ID: 7484441
    [No Abstract]   [Full Text] [Related]  

  • 23. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome.
    Orvieto R; Achiron A; Margalit R; Ben-Rafael Z
    J Assist Reprod Genet; 1998 Jan; 15(1):46-9. PubMed ID: 9493066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model.
    Fainaru O; Hornstein MD; Folkman J
    Fertil Steril; 2009 Nov; 92(5):1701-5. PubMed ID: 18937946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary.
    Yarali H; Fleige-Zahradka BG; Yuen BH; McComb PF
    Fertil Steril; 1993 Mar; 59(3):657-61. PubMed ID: 8458471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
    Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
    Guazzi M; Agostoni P
    Clin Sci (Lond); 1999 Jan; 96(1):17-22. PubMed ID: 9857102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. A pilot experimental study.
    Orvieto R; Abir R; Kaplan B; Bar-Hava I; Ben-Rafael Z
    Clin Exp Obstet Gynecol; 1999; 26(2):98-9. PubMed ID: 10459449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo reactivity of the ovarian vascular bed to noradrenaline and carbachol during ovarian hyperstimulation syndrome.
    Oriowo MA
    Med Princ Pract; 2004; 13(3):115-21. PubMed ID: 15073421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.
    Ujioka T; Matsuura K; Tanaka N; Okamura H
    Hum Reprod; 1998 Nov; 13(11):3009-15. PubMed ID: 9853847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
    Kitsou C; Kosmas I; Lazaros L; Hatzi E; Euaggelou A; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos K; Galani V; Georgiou I
    Gynecol Endocrinol; 2014 Aug; 30(8):587-92. PubMed ID: 24819316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.